Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. - Wikidata - wikimedia - TriplyDB

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

http://www.wikidata.org/entity/Q35578577

about

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer Internal radiation therapy: a neglected aspect of nuclear medicine in the molecular era Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Progress in molecular-based management of differentiated thyroid cancer MYC activation is a hallmark of cancer initiation and maintenance Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF BRAF activates and physically interacts with PAK to regulate cell motility Integrated genomic characterization of papillary thyroid carcinoma 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.Update: the status of clinical trials with kinase inhibitors in thyroid cancer Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells.Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo.Flavonoids, Thyroid Iodide Uptake and Thyroid Cancer-A Review.Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment Molecular pathogenesis and mechanisms of thyroid cancer Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1 Association of the ATM gene polymorphisms with papillary thyroid cancer.Modulation of sodium iodide symporter in thyroid cancer Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and Apigenin Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF Epigenetics modifications and therapeutic prospects in human thyroid cancer.Poorly differentiated thyroid carcinoma: an incubating entity.SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Mouse models of thyroid cancer: A 2015 update.Novel Approaches to Thyroid Cancer Treatment and Response Assessment.Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.Evolving approaches to patients with advanced differentiated thyroid cancer Targeting thyroid cancer microenvironment: basic research and clinical applications.Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.MEK inhibition leads to lysosome-mediated Na+/I- symporter protein degradation in human breast cancer cells.

P2860

Q24596266-3AA7340F-848D-4ABD-887A-5E86DFF56616 Q26786554-71E06AC0-C27F-4A22-889F-B1ABC24E535B Q26853261-33B8CDDA-8063-4937-BF97-416479B8C7FB Q26863326-BA02AD31-39F7-4650-8446-ADD2F8D00F12 Q26999887-1C22B0A6-1582-431A-84A0-2A9224AC66C7 Q27026026-C918BA1A-2E5C-481E-8605-40D2614A50D4 Q27027491-FD11C178-A5CA-473E-9A5C-DD087D386BB7 Q27853045-1081BF82-257C-4F67-A11A-CF94445BA7A7 Q28248127-48AAA2D9-B6A1-4EB6-90CB-B8F35175064C Q28251986-62084251-9831-4151-878E-1D5FAC210B7E Q30367068-E2DB024C-259A-43B8-8F58-6D66DFDDCEDC Q33558907-C270759D-60C1-4FFE-98A6-49F993E4FBBA Q33570056-BDC2F5F8-EDD6-469D-A107-CA7F9C339E78 Q33587905-211508E9-FA41-4398-B5D5-D037C3DDC38B Q33632438-93464549-792C-41E6-B825-A7CC0B07E68F Q33648582-D64A017F-BC87-4421-8435-B6E2F2B2A9AA Q33838859-15845698-42D7-43C3-B9F3-55C914FB11F7 Q34123525-0C721E45-D376-4833-838B-61D35E9EC36F Q34137706-C26245EF-BC67-45D6-B120-D7EBF165E971 Q34329018-092F7D48-16A3-4FCD-9895-7EA6517AC760 Q34571096-12E487F8-14AD-41AF-B2F9-6C90C4D46E79 Q34669305-95D71F2F-C8BE-4BE0-B262-39286DDC8B51 Q34909764-A9248DAE-2CA8-4C60-B30A-BAF5FF0A69E4 Q35690173-7B335CAF-B04A-47E1-BB41-556DA5DD3D24 Q35784584-2EF1F53E-AE15-4EA2-8D71-A8C8EF0738F2 Q35797331-03770F6A-63FF-482B-B40D-3854299ED191 Q35914464-CA64B5F0-516F-4999-91B6-127F794C3749 Q35971504-E0E64469-7FE8-4750-9DB3-C97D947E3544 Q36050222-F101D2A3-7982-4AAD-AA62-D23A049CB8FE Q36118305-354016BB-40AF-48E0-9646-C20956266FE3 Q36255616-2396F2C4-8F6F-4843-A2F1-1125FFAA884E Q36405539-679BA6EF-FA56-4D71-958E-AF86EFC26FC8 Q36602187-262D5511-F981-43BD-A45A-F9F6196B36B8 Q36618887-CB1CB73B-22F7-414C-83BB-AF89FFFC08CB Q36817229-39E33AD8-3C10-4A49-8C7F-8385BA9D633F Q36864736-55E91897-7F1B-4756-B93C-7650A0E0C0FC Q37275748-169DBF8D-357D-410F-BEC6-59B84921F570 Q37281596-D769A2C4-71AA-42A9-8BE6-9DC90CEDB09A Q37293444-D55B00F6-B986-4F58-AA9C-FBAB244E9BD0 Q37334755-69E1ED20-8220-4ED5-98D8-249CC2A8694D

P2860

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

http://www.wikidata.org/entity/Q35578577

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Small-molecule MAPK inhibitors ...... h conditional BRAF activation.

@ast

Small-molecule MAPK inhibitors ...... h conditional BRAF activation.

@en

type

label

Small-molecule MAPK inhibitors ...... h conditional BRAF activation.

@ast

Small-molecule MAPK inhibitors ...... h conditional BRAF activation.

@en

prefLabel

Small-molecule MAPK inhibitors ...... h conditional BRAF activation.

@ast

Small-molecule MAPK inhibitors ...... h conditional BRAF activation.

@en

P1433

Q35578577-61F609DC-B9FB-45DA-AA5C-1DA7F72AF57E

P1476

Q35578577-7BC9177E-69BF-4EEB-B2EF-E2840B9EE0DD

P2093

Q35578577-058FB05B-217A-4194-BA5A-78BB4E4E3575

Q35578577-123ED498-A277-45D6-893D-E51E5BF0371D

Q35578577-143E9479-484B-4D88-89DF-6E29B79E46EE

Q35578577-4FF9E4FC-DD14-4180-B848-2B8B65796FF1

Q35578577-77B10962-1C54-454B-8824-21555E39E9A6

Q35578577-8DE2A6ED-D289-4A69-8FB8-4F757484C2EB

Q35578577-93D278C3-41E5-4432-9998-C8F1E01E4AA0

Q35578577-ACF5655D-CC77-44B8-93DE-E4426A6B788E

Q35578577-CBE4A4F8-5847-4BCD-B076-A5371108FF2D

Q35578577-D865C489-DC10-48D1-B9DE-55E8671B272D

P2860

Q35578577-05CE62DF-C966-4502-BA1C-D1103CA3685A

Q35578577-08C85B86-ABC6-4105-B1B3-34C898A5A07B

Q35578577-136BB484-ED20-4FB3-8E52-47C8909EE07A

Q35578577-13767F44-AC6B-409F-B42E-DA32F9F03124

Q35578577-14709977-E8DC-409D-B63E-FF333FC529A1

Q35578577-16D58004-D330-4043-B65B-810F19858378

Q35578577-18B41D58-A83D-4FCE-A8AC-5D638FFEEB02

Q35578577-1CE2DD48-B36B-4590-A7B3-1EBE8D1CE93C

Q35578577-26E714A6-2654-443F-BA45-A153E555B683

Q35578577-26F8C978-7798-4DB1-86C5-407DBE8A9330

P304

Q35578577-55B9FBA0-4896-458E-8EE0-6FD1634B9687

P31

Q35578577-2F35A712-0A83-4319-AA0D-B709D51902E7

P356

Q35578577-7B49A3D2-CAAB-41AB-BAE2-EF2C76D4F9DD

P407

Q35578577-3B52292A-9E92-45D8-9018-027CE8252A65

P433

Q35578577-AA9168F2-F020-44C1-B997-B0E03AFC6AFD

P478

Q35578577-8AD64F7E-0B15-4E0C-A3C7-EA3E69F0CEE7

P50

Q35578577-C33D5AD1-B65A-4E52-990A-2F3F1703B4BC

Q35578577-CA92AA0D-43E7-4EB4-A61D-CC1E30C7784F

Q35578577-E18B0D03-D786-4D6B-80BC-3AE37C4CD4FB

P577

Q35578577-23EDC4CE-690E-4474-A8B9-109595865DEA

P698

Q35578577-4577E61C-A751-4054-8207-4338EDFC74B0

P932

Q35578577-CA7738CE-D136-4311-A5D1-97AF233E0F63

P356

P1433

Journal of Clinical Investigation

P1476

Small-molecule MAPK inhibitors ...... h conditional BRAF activation.

@en

P2093

Brian L West

http://www.w3.org/2001/XMLSchema#string

Elmer Santos

http://www.w3.org/2001/XMLSchema#string

James A Fagin

http://www.w3.org/2001/XMLSchema#string

Mabel Ryder

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Pat Zanzonico

http://www.w3.org/2001/XMLSchema#string

Richard Kolesnick

http://www.w3.org/2001/XMLSchema#string

Ronald Ghossein

http://www.w3.org/2001/XMLSchema#string

Samuel Refetoff

http://www.w3.org/2001/XMLSchema#string

Steven M Larson

http://www.w3.org/2001/XMLSchema#string

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes

Cancer. Addiction to oncogenes--the Achilles heal of cancer

BRAF mutation predicts sensitivity to MEK inhibition

P304

4700-4711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI46382

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Debyani Chakravarty

Jeffrey A Knauf

P577

2011-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22105174

http://www.w3.org/2001/XMLSchema#string

P932

3225989

http://www.w3.org/2001/XMLSchema#string